XenoPort MS treatment fails in late-stage testing

Mon, 05/20/2013 - 12:01pm
The Associated Press

Shares of XenoPort Inc. sank Monday after the drug developer said a potential treatment for multiple sclerosis patients failed in late-stage clinical testing, and it will stop developing the drug.

The Santa Clara, Calif., company said the treatment, labeled arbaclofen placarbil, failed to show a statistically significant improvement for patients taking it compared to a fake drug. XenoPort was testing the drug to treat patients with spasticity due to multiple sclerosis.

The study involved 228 patients at 30 U.S. sites.

Spasticity is a condition connected to some neurological disorders and injury to the spinal cord. It can cause decreased range of motion, weakness, and coordination problems. Multiple sclerosis is a disease in which the immune system attacks healthy nerves. It can cause pain, numbness, slurred speech, impaired vision, muscle weakness, and neurological problems.


Share This Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.